Finding the Next TechBio Unicorn with Krish Ramadurai, AIX Ventures

Ever wonder what separates a billion-dollar TechBio unicorn from a well-funded experiment? Krish Ramadurai of AIX Ventures does—and he's backed some of the coolest ones. We dive into why understanding the actual science matters, why mice are terrible at predicting human outcomes (sorry, lab mice), and how the next generation of drug discovery is being built by teams brave enough to let AI nerds and wet lab scientists actually talk to each other. Plus, he'll tell you why he thinks you should care about making drugs people can actually afford.